.jpeg)
2026-04-28 04:12:36
This article details the approved indications and mechanism of action of sopyrronium bromide (brand name Sofdra), an anticholinergic medication, focusing on the core reasons why it is not recommended for facial hyperhidrosis, relevant safety precautions, and alternative treatment options.
2026-04-21 02:42:40
Icotyde (generic name: Icotrokinra) is a medication that works by modulating the immune system. It has a relatively mild overall side effect profile, but still requires close monitoring of drug reactions by patients and healthcare providers. This article details its common side effects and targeted mitigation strategies, core pharmacokinetic characteristics, and standard drug storage requirements.
2026-04-03 06:57:16
Deucravacitinib (brand name Sotyktu, Chinese trade name Songdiduo) is a next-generation, oral, highly selective TYK2 inhibitor developed for the pathological mechanism of psoriasis. Approved in multiple countries and regions worldwide for the systemic treatment of adults with moderate-to-severe plaque psoriasis, it precisely modulates inflammatory pathways to improve skin lesions, with the advantages of rapid onset, durable long-term efficacy, and convenient oral administration, providing a non-injectable, non-biologic treatment option for patients with psoriasis.
2026-03-18 05:32:12
Apremilast is an oral small-molecule PDE4 inhibitor used to treat psoriasis, psoriatic arthritis and Behcet's disease. This article explains its mechanism, efficacy and safety.
2026-03-12 03:31:19
Remibrutinib (brand name Ruipoduo) is a highly selective Bruton's tyrosine kinase (BTK) inhibitor for chronic spontaneous urticaria. Clinical studies show good safety and tolerability, with common side effects including headache and gastrointestinal reactions. Infection prevention, hematological monitoring, and long-term follow-up are key.
